Literature DB >> 31112499

Inpatient Management of Acute Severe Ulcerative Colitis.

David I Fudman1, Lindsey Sattler2, Joseph D Feuerstein2.   

Abstract

Acute severe ulcerative colitis (ASUC) is a potentially life-threatening presentation of ulcerative colitis that in nearly all cases requires inpatient management and coordinated care from hospitalists, gastroenterologists, and surgeons. Even with ideal care, a substantial proportion of patients will ultimately require colectomy, but most patients can avoid surgery with intravenous corticosteroid treatment and if needed, appropriate rescue therapy with infliximab or cyclosporine. In-hospital management requires not only therapies to reduce the inflammation at the heart of the disease process, but also to avoid complications of the disease and its treatment. Care for ASUC must be anticipatory, with patient education and evaluation starting at the time of admission in advance of the possible need for urgent medical or surgical rescue therapy. Here we outline a general approach to the treatment of patients hospitalized with ASUC, highlighting the common pitfalls and critical points in management.

Entities:  

Year:  2019        PMID: 31112499     DOI: 10.12788/jhm.3207

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  3 in total

1.  Hospital Management of Acute Severe Ulcerative Colitis.

Authors:  Joseph Feuerstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-03

2.  Rectal administration of Panax notoginseng and Colla Corii Asini suppositories in ulcerative colitis: clinical effect and influence on immune function.

Authors:  Li Zeng; Xiaohai Li; Guomin Bai; Yu Liu; Qingge Lu
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

3.  The combined efficacy of adalimumab with GMA method on the treatment of ulcerative colitis and repair of intestinal mucosal lesion.

Authors:  Ailing Song; Hai Jiang; Liang Guo; Shanshan Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.